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Abstract
Background: To describe the clinical phenotype of paroxysmal extreme pain disorder, an autosomal dominant
condition in four members in one family with the mutation NM_002977.3:c.3892G > T (p.Val1298Phe) in the SCN9A
gene. Clinical examinations and details from members of one Polish family were collected, including age at onset,
features of attacks, problems between attacks, investigational results, treatments tried, and evolution over time.
Case presentation: Twenty two individuals from this family with paroxysmal extreme pain disorder were identified.
Seven of them presented clinical manifestation of paroxysmal extreme pain disorder, of which and in four were
identified missens mutations in the SCN9A gene (NM_002977.3:c.3892G > T). The onset of the disorder took place in
the neonatal period or infancy and persists throughout life. Autonomic manifestations predominate with extreme
pain, skin flushing and harlequin colour change were observed in all. Attacks of excruciating deep burning pain
often appear in the rectal, or jaw areas, but also diffuse in the body. Attacks are triggered by factors such as:
defecation, eating, pressure and emotion. Carbamazepine and other antiepileptic drugs were only partly effective in
almost all, but the response was incomplete.
Conclusions: Paroxysmal extreme pain disorder is a hereditary sodium channelopathy with pain and an autonomic
nervous system dysfunction. Paroxysmal extreme pain disorder is rare, so far only 500 cases of both women and
men have been described in world literature.
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Background
Paroxysmal extreme pain disorder (PEPD) is a genetic-
ally conditioned autosomally dominantly inherited
chronic disease characterized by attacks of severe pain
located in various areas of the body combined with skin
flashing. The mutation refers to the SCN9A gene encod-
ing proteins forming the NaV1.7 sodium channel in sym-
pathetic ganglia neurons [1]. The disorder is rare, so far
only 500 cases of both women and men have been de-
scribed in world literature [2, 3].
Clinical symptoms are characterized by attacks of rap-
idly developing burning, lancinating pain in the rectal,
ocular and mandibular areas with skin flashing in a har-
lequin pattern. The pain lasts from a few seconds to sev-
eral hours. It may be accompanied by apnoea, high
blood pressure, asystole or epileptic seizures. The first
symptoms of the disease usually appear during infancy.
Most often their appearance is related to provocative
factors such as: defecation, eating, taking medications,
micturition, gynaecological examination, rectal examin-
ation, stress or even touch [1, 2, 4]. In the presented
family on the basis of the typical features of the attacks,
a diagnosis of paroxysmal extreme pain disorder (PEPD)
was made and confirmed by molecular genetics.
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Clinical examinations and details from four members
of one Polish family were collected, including age at on-
set, features of attacks, problems between attacks, inves-
tigational results, treatments tried, and evolution over
time. Twenty two individuals from this family with par-
oxysmal extreme pain disorder were identified (Fig.1).
Case presentation
The 44-year-old patient (patient IV.3) applied for the
consultation because of many years of recurrent attacks
of severe pain of a tearing character and significant in-
tensity located in different parts of the body. Initially,
the pain attacks were located only in the perineum area;
they appeared suddenly and lasted from a few seconds
to several minutes. They were preceded by a triggering
factor, such as: irritation of the perineum area (e.g. dur-
ing defecation), pressure, scratch or a stressful situation.
The pain was accompanied by additional symptoms,
which varied depending on the patient’s age. The patient
reported that the first episode had occurred at the age of
about 8 months, during passing stool, when the cry had
been accompanied by bending the body into a “cradle”
and apnoea. The patient remembers the attacks from
about the age of 7–8. At that time, the pain was accom-
panied by shortness of breath, flushing of half or parts of
the body (e.g. half the chest as well as ocular and submax-
illary regions) and a hot feeling on the side of flushing.
The pain was most often felt to appear in superficial tis-
sues, but could also be felt in deep tissues during severe
attacks. At a later age, the location of pain during the at-
tacks changed - there were headaches accompanied by
tearing or abdominal pain. No abnormalities were de-
tected in the additional examinations, including cerebral
MRI, EEG and ECG. The patient took carbamazepine in
the past, which turned out to be ineffective. Currently, a
partial improvement and an alleviation of symptoms have
been achieved using topiramate and pregabalin. Despite
these problems, the patient’s lifestyle is normal and there
is no experience of any other additional disability.
Similar symptoms occur in the 20-year-old (patient
V.2) and 25-year-old (patient V.3) daughters of the pa-
tient. They were repeatedly hospitalized in their child-
hood due to the presence of apnoeas, convulsions,
contractures of the limbs or fainting. The picture of
these attacks also changed with their age. In the older
daughter the first episode occurred at the age of 2.5
months, during a bath, in the form of body flushing, ap-
noea with spontaneous breath back, vociferous crying,
fatigue and flaccidity of the muscles. During the first
hospitalization, the pain attack occurred during the rec-
tal examination in the form of several deep breaths
followed by apnoea and spontaneous breath back, and
then drowsiness lasting about 1–2 min, body flashing
and the increase of the right lower limb warmth were
observed. In the early childhood, the episodes of pain
were accompanied by loss of consciousness, with urinat-
ing and biting the tongue. The pain attacks also oc-
curred in the night in the form of severe headaches with
half the face flashing, and eye tearing on the side of
flashing. After the attack, which regressed spontan-
eously, intense sweating, mainly in the head occurred.
Periodically, also the attacks of abdominal pain or head-
aches with flashing of the skin layers were observed
(Figs. 2, 3, 4, 5). The attacks were preceded by a painful
or emotional stimulus. During the teenage period, faint-
ing dominated and later contractures of the upper limbs
joined. Between attacks, the patient’s neurological devel-
opment was normal.
Fig. 1 A six-generation pedigree displaying affected members of the family
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During attacks, hypersensitivity of the skin at the side
of redness and increased sweating were observed in all
patients (IV.3, V.2, V.3). Between attacks, the assessment
of sensory and autonomic functions was correct. No
changes were found in neurological examination either.
No abnormalities were revealed in the repeatedly per-
formed haematological, biochemical investigations as
well as head imaging examinations, including MRI and
an electroencephalographic examination. So far, none of
these patients has been treated chronically for another
reason.
The older daughter’s four-year old son (patient VI.1)
also suffers from excruciating pain and flushing upon be-
nign mechanical or heat stimuli mostly in rectal or abdo-
men regions. A typical episode appeared during the first
few days of his life, with paroxysmal painful events that
started with tonic contraction of the whole body followed
by erythematous harlequin-type colour changes. After the
attack, which regressed spontaneously, the infant experi-
enced intense sweating.
The genetic test was performed in four family mem-
bers. All four tests confirmed the heterozygous mutation
Fig. 2 Harlequin flushing in family members during episodes of
paroxysmal extreme pain disorder
Fig. 3 Harlequin flushing in family members during episodes of
paroxysmal extreme pain disorder
Fig. 4 Harlequin flushing in family members during episodes of
paroxysmal extreme pain disorder
Fig. 5 Harlequin flushing in family members during episodes of
paroxysmal extreme pain disorder
Stępień et al. BMC Neurology          (2020) 20:182 Page 3 of 5
NM_002977.3:c.3892G > T (p.Val1298Phe) in the SCN9A
gene (Fig.1). Genetic test was made with Sanger method.
Discussion and conclusions
Mutations in the SCN9A gene are the cause of a hetero-
geneous channelopathy pain syndrome including small
nerve fiber neuropathy, inherited erythromelalgia and
PEPD. In the presented family with PEPD NM_
002977.3:c.3892G > T (p.Val1298Phe) missens mutation
in the SCN9A gene was detected. This mutation is re-
ported in ClinVar Database (variation ID 6358;
rs121908912) as patogenic in PEPD.
Recurrent episodes of pain in all members of the fam-
ily affected different body parts and were accompanied
by autonomic manifestations, such as: skin flushing and
swelling of the skin, which occur in a harlequin pattern.
The recognition of PEPD is based on the diagnosis of
a characteristic set of symptoms, a course of the disease
and a genetic test. In the initial period it can be difficult
and requires numerous diagnostic tests that exclude
other than the genetic mutation background of the dis-
ease. The first description of the disease was made by
Hayden and Grossman in 1959 [5]. It was then noted
that patients often experienced attacks of very strong
burning pain in the rectal area during defecation. In later
reports, it has been observed that pain attacks with skin
flushing can also be located on the trunk, head or limbs,
and the trigger can be touch or stress. The first symp-
toms of the disease may appear immediately after a
childbirth in the neonatal period. The disease is associ-
ated with the occurrence of “mutations” in the SCN9A
gene located in the 2q24.3 chromosome coding for alpha
subunit of the potential-dependent NaV1.7 sodium chan-
nels. These channels are mainly expressed in peripheral
somatic and visceral sensory nerves, nociceptoras, dorsal
roots of the spinal cord, trigeminal ganglion, olfactory
cells and sympathetic ganglion [2]. The relationship of
NaV1.7 with the feeling of pain was confirmed, and the
presence of a homozygous SCN9A gene mutation caus-
ing loss of the channel function is associated with a
complete inability to feel pain (congenital pain insensi-
tivity syndrome) [6]. The mutation triggering PEPD
causes the creation of NaV1.7 channels with a changed
function, which interferes with the inactivation process.
The extension of the phase of rapid inactivation of the
channels, generating of the constant sodium current and
the increased excitability of neurons occur [7]. Due to
literature, authors of molecular study of SCN9A gene in
PEPD were identified eight mutations of SCN9A in these
disease [1]. In these mutations was also identified muta-
tion which was found in described family. At present, ac-
cording to the ClinVar database and literature, ten
PEPD-related mutations are known [2]. Eight of them
are pathogenic for PEPD. Clinically defined PEPD do
not always harbour the SCN9A gene mutation [8]. For
example, erythema and burning pain in the lower parts
of the body, more classically a primary erythromelalgia
description, is harbouring the M1627K mutation of
SCN9A gene [9]. As far as the diversity of symptoms and
different genetic origins are concerned, a clinical diagno-
sis of PEPD might encompass different entities. In the
described family, there is a consensus between the
SCN9A gene mutation and the phenotype.
Symptoms of PEPD occur throughout the entire life of
an individuals with PEPD [8]. However, the frequency
and nature of attacks vary with age, with the highest in-
tensity during infancy and early childhood. Tonic none-
pileptic seizures are more characteristic of infancy and
early childhood, but may also occur in adults. These are
accompanied by apnoea, flushing, bradycardia and skin
changes of the harlequin type, without crying. In a later
age, an attack changes its image slightly, starting from
an inconsolable screaming that changes into apnoea, pal-
lor and stiffness. Such an episode lasts from a few sec-
onds to a few minutes and then the breath comes back
spontaneously. After the attack, there is an impaired
contact and flaccid for a few minutes [8]. They may be
accompanied by periods of extended asystole requiring
resuscitation. So far, no individual’s death has been re-
corded as directly caused by a sudden circulatory arrest
in the course of a pain attack [3]. During late childhood
and in adults, ocular and mandibular attacks may occur
more frequently. The number of attacks caused by irrita-
tion of the rectal area is reduced by the use of methods
to prevent constipation and a learned way of defecation
[8]. Between attacks, individuals complain of constipa-
tions, which may be caused by fear of triggering an at-
tack. Till now, there has been no study assessing the
impact of PEPD on the psychic and psychological status
of subjects, however, cases of depression and drug abuse
are observed in these group. The cognitive and intellec-
tual level of individuals with PEPD is similar to the gen-
eral population [7, 8].
A genetic test in PEDS is indicated when there is:
● pain of a similar nature of symptoms in > 2 family
members.
● pain of unknown aetiology at an early age.
● unusual picture of the disease.
● another genetic disorder that may be contributing to
pain [2].
Currently, we do not have any causal treatment for
paroxysmal extreme pain disorder. Treatment is based
on the use of sodium channel inhibitors. Antiepileptic
drugs, tricyclic antidepressants and inhibitors of the re-
absorption of serotonin and noradrenaline are used. The
drug of choice in PEPD is carbamazepine [8]. It is ob-
served to be partially effective in reducing the number
and severity of attacks in the majority of subjects with
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PEPD, and in individual cases even their complete elimin-
ation. It seems that other antiepileptic drugs are partially
effective in some cases, e.g. gabapentin, topiramate or
lamotrigine. The use of amitriptyline, clonidine and intra-
venous lidocaine does not bring the desired effect. Opioid
drugs are not recommended due to both their ineffective-
ness and the possibility of increased constipation. In chil-
dren, in cases of the strongest attacks, an improvement is
obtained after using a 1: 1 mixture of nitrous oxide and
oxygen [8, 10]. In the literature the beneficial effects of
pelvic floor muscle exercises and the prevention of consti-
pation are described [2]. In circumscribed cases only a
very limited range response for antiepileptic drugs and tri-
cyclic antidepressants was observed.
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